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Background: It has been reported recently that resveratrol preconditioning can protect the brain from ischemia–
reperfusion injury. However, it was unclear whether resveratrol administration after stroke was beneficial to the delayed
phases after focal cerebral ischemia injury. This study investigated the effects and possible protective mechanism of
resveratrol on the delayed phase after focal cerebral ischemia injury in mice.
Methods: Mice were randomly assigned to five groups according to the time of administration of resveratrol. Control
group mice received a corresponding volume of saline solution (0.9% NaCl) containing 20% hydroxypropyl h-
cyclodextrin by gavage and were exposed to middle cerebral artery (MCA) occlusion and reperfusion injury. The
treatment groups received resveratrol (50 mg/kg/d, gavage) until day 7. Ischemia group mice received their first dose 5
minutes before MCA ischemia, reperfusion group mice received their first dose 5 minutes before MCA reperfusion,
first-day, group mice received their first dose 24 hours after MCA reperfusion, and third-day group mice received their
first dose at 72 hours after MCA reperfusion. Brain injury was evaluated by triphenyltetrazolium chloride staining and
neurologic examination 7 days after reperfusion. The microvascular cell number was examined with immunohistochem-
istry staining. Effect of resveratrol on matrix metalloproteinase-2 (MMP-2) and vascular endothelial growth factor
(VEGF) gene expression was investigated with reverse transcriptase-polymerase chain reaction and Western blot.
Results: The mean neurologic scores and infarct volumes of the ischemia and reperfusion groups were lower than that of
the control group at 7 days after MCA reperfusion (P < .05). Immunohistochemistry staining showed significantly less
reduction in the number of microvessels in the cortical area of mice of the ischemia and reperfusion groups compared with
controls. The ischemic hemispheres of the ischemia and reperfusion groups showed significantly (P< .05) elevated levels
of protein of MMP-2 and VEGF.
Conclusions: Resveratrol administration by gavage provided an important neuroprotective effect on focal cerebral
ischemic injury in the delayed phase. The elevated MMP-2 and VEGF levels might be important in the neuroprotective
effect of resveratrol administration by inducing angiogenesis. ( J Vasc Surg 2008;48:709-14.)
Clinical Relevance: Strokes can induce infarction size or neurologic disability and cause brain injury in millions of people
world wide each year. However, there is no approved therapy currently, and so it is necessary to develop new treatments
in the field of primary and secondary stroke to improve the prognosis. This study identified the benefits of early
administration of resveratrol by gavage in the delayed phases after focal cerebral ischemic injury and further supports the
possible use of resveratrol as a therapeutic agent to ameliorate ischemic infarction. Resveratrol may thus be considered as
a potential candidate in the armamentarium of drugs for the early treatment in patients who sustain a stroke.Stroke causes 5.5million deaths and the loss of 49million
disability-adjusted life-years worldwide each year.1,2 In the
Western world, ischemic stroke is a leading cause of death and
disability. Although the incidence andmortality of stroke have
been decreasing regularly over time, development of new
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doi:10.1016/j.jvs.2008.04.007treatments during the acute phase in the field of primary and
secondary stroke prevention is still necessary to improve prog-
nosis.3 The focus of current research is, therefore, to find
novel drugs to be used in the therapy for ischemic stroke.
Resveratrol (3,4=,5-trihydroxy-trans-stilbene), a natural
polyphenolic compound, is found in a few edible materi-
als.4 In addition to inhibiting carcinogenesis at multiple
stages in a wide variety of cancer models,5,6 decreasing
platelet aggregation,7 enhancing stress resistance, and ex-
tending the lifespan of various organisms from yeast8 to
vertebrates,9 it is also confirmed that resveratrol reduces
infarction volume and decreases brain water content at an
extremely low dosage in a variety of in vitro and in vivo
models for cerebral ischemic stroke.10-13
Huang et al13 first showed that a low dosage of resvera-
trol was able to effectively reduce the infarct volume in
Long-Evans rats subjected to focal cerebral ischemia, with-
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of male Wistar rats14 that reported that resveratrol precon-
ditioning prevented motor impairment, increased the levels
of malondialdehyde, reduced glutathione, and decreased
the volume of infarct after middle cerebral artery occlusion
at the dose of 20 mg/kg intraperitoneally for 21 days.
In rat hippocampal neurons, resveratrol inhibited voltage-
activated K currents, suggesting that it may be useful
for treating ischemic brain injury.15 In addition, resvera-
trol has been found to ameliorate cell death through
phosphoinositide3-kinase pathway in organotypic hip-
pocampal cultures exposed to oxygen-glucose depriva-
tion.16 Resveratrol also decreased delayed neuronal cell
death and glial cell activation in the hippocampus in
Mongolian gerbils after stroke induced by the occlusion
of common carotid arteries.17
Previous studies about the role of resveratrol in
ischemic–reperfusion injury have concentrated on resvera-
trol preconditioning.10-17 If we can confirm that resveratrol
treatment after ischemia was beneficial for brain protection
and neurologic function recovery during the delayed phase,
perhaps we can find a novel therapy for promoting recovery
of ischemic–reperfusion injury.
In our study we examined the effect of resveratrol in the
mouse model of focal cerebral ischemia. The neuroprotec-
tion was evaluated by infarct volume measurements and
neurologic examination. Meanwhile, stroke recovery is
closely associated with neuronal plasticity, neurogenesis,
and angiogenesis. Matrix metalloproteinase-2 (MMP-2)
and vascular endothelial growth factor (VEGF) are crucial
for this process because they can remodel components
involved in extracellular matrix and blood vessel formation.
So the effects of resveratrol on MMP-2 and VEGF gene
expression in the delayed phase after middle cerebral artery
(MCA) occlusion in mice were investigated to provide a
mechanistic basis for the protective effect of resveratrol on
cerebral ischemia–reperfusion.
MATERIAL AND METHODS
Animals. Cerebral focal ischemia surgery was per-
formed in adult male Balb/c mice, weighing 28 to 32 g,
obtained from the animal center of the Fourth Military
Medical University. Mice were allowed free access to water
and chow until surgery. Resveratrol (Sigma, St Louis, Mo)
was prepared at a concentration of 6 mg/mL in saline
solution (0.9% NaCl) containing 20% hydroxypropyl
h-cyclodextrin (American Maize-Products Co, Hammond,
Ind). Mice were weighed, and resveratrol was adminis-
trated orally (50 mg/kg/d) to intact mice by gavage after
surgery. Mice were euthanized with an overdose of pento-
barbital 7 days after MCA reperfusion.
Experimental groups. All mice were randomly as-
signed to five groups according to the time of administra-
tion of resveratrol. Control group (CG) mice received a
corresponding volume of saline solution (0.9% NaCl) con-
taining 20% hydroxypropyl h-cyclodextrin by gavage and
were exposed toMCA occlusion and reperfusion injury. All
mice in the treatment groups were treated with resveratrol(50 mg/kg/d, gavage) until day 7. Ischemia group (IG)
mice and reperfusion group (RG) mice received their first
dose 5 minutes before MCA ischemia and reperfusion,
respectively. First-day group (OG) mice received their first
dose 24 hours after MCA reperfusion, and third-day group
(TG) mice received their first dose 72 hours after MCA
reperfusion.
Induction of focal cerebral ischemia. Mice were
anesthetized with 2.5% halothane for induction and main-
tained with 1.0% to 1.5% halothane in 70% nitrous oxide
and 30% oxygen with a face mask. Sufficiency of occlusion
and reperfusion of the MCA were monitored by laser
Doppler flowmetry. MCA occlusion was induced with an
8-0 nylon monofilament coated with a silicone hardener
mixture through the internal carotid artery, as described.18
Anesthesia did not exceed 15 minutes. After 2 hours of
ischemia, the animals were reanesthetized for 2 minutes
and reperfusion was induced by removing the monofila-
ment. Body temperature was maintained at 37°C until
recovery from anesthesia.
Neurologic examination. Neurologic examination
was performed before euthanasia. A neurologic grading
system with a 5-point scale (0 to 4), described by Menzies
et al,19 was used: 0, no apparent deficits; 1, left forelimb
flexion; 2, decreased grip of the left forelimb while the tail
is pulled; 3, spontaneous movement in all directions; left
circling only if pulled by the tail; 4, spontaneous left cir-
cling.
Infarct volume measurement. Seven days after reper-
fusion, animals (n  8 for each group) were euthanized
with an overdose of pentobarbital anesthesia, and the brains
were removed. For 2,3,5-triphenyltetrazolium chloride
(TTC)-stained sections, brains were sectioned coronally
into four 2-mm slices in a mouse brain matrix (RBM-
2000C; Activational Systems, Ann Arbor, Mich). Slices
were stained with 2.5% TTC (Sigma) in phoshate-buffered
saline (PBS), followed by 10% formalin overnight. The
infarct area of each TTC-stained section was measured
using an image analysis system on the posterior surface of
each section.
Because larger infarcts were associated with significant
edema, areas in each section were corrected for edema as
follows. The relative size of the cortical infarct was ex-
pressed as a percentage: [100%  (contralateral cortex 
[total ipsilateral cortex  cortical infarct])/ipsilateral cor-
tex]. The relative size of each striatal infarct was similarly
corrected. Corresponding volumes were then calculated for
the total set of slices. All measurements were done by an
investigator blinded to treatment assignment.
Immunohistochemistry. To examine the microvas-
cular cell number, a rabbit polyclonal anti-CD34 antibody
(Boster, China) against human andmouse was used to stain
the vascular endothelial cells.
Staining protocol. The pieces were fixed for 6 hours
in 10% neutral phosphate-buffered formalin. Tissues were
dehydrated using graded alcohols, cleared with xylene, and
embedded in paraffin wax. To minimize antigen denatural-
ization, tissues were not exposed to temperatures 60°C
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2-m sections were collected on poly-L coated slides. The
tissue sections were deparaffinized in xylene (10 minutes,
twice) and rehydrated in a graded ethanol series up to
distilled water.
For heat-induced antigen retrieval, the samples were
treated for 2 minutes in an autoclave at 121°C containing
10% citrate buffer. After washing twice with PBS (pH 7.4)
for 3 minutes, the sections were treated with 0.3% hydro-
gen peroxide in the methanol for 30 minutes at room
temperature to inhibit endogenous peroxidase activity. Af-
ter washing three times with PBS for 30 minutes, these
sections were blocked with 0.1M PBS plus 3% skimmed
milk and 3% goat serum for 2 hours at room temperature,
and washed twice in distilled water and PBS for 3 minutes.
The anti-CD34 antibody diluted in 0.1M PBS (1:200) was
applied onto the sections, and these sections were main-
tained 48 hours at 4°C in a humidified chamber, and
afterwards washed twice in PBS for 3 minutes. The tissue
sections was covered with a peroxidase-based secondary
antibody for 30 minutes and then washed in PBS for 5
minutes.
To confirm the presence of immunocomplexes, 3,3=-
diaminobenzidine (DAB) was used as a chromogene.
The samples were washed twice in distilled water, con-
trasted with Mayer’s hematoxylin for 1 minute, rinsed
gently with tap water, dehydrated in a graded series of
ethanol, cleared in xylene, and cover slipped with 1,3,
-diethyl-8-phenylxanthine. Digital microscope images
were captured by means of an Olympus CH 30 micro-
scope (Olympus, Tokyo, Japan). Negative controls were
made by omission of the primary antibody.
Quantification of microvessels. Microscopic analysis
was performed by one independent pathologist. The num-
ber of CD34-tained microvessels in every section was de-
termined on the ischemic side and the nonischemic side.
Vessels with a clearly defined lumen or well-defined linear
vessel shape, but not single endothelial cells, were consid-
ered for microvascular assessment. The number of mi-
crovessels detected in the basal ganglia and cortex on the
ischemic side were compared with the number of microves-
sels in the nonischemic hemisphere.
RNA isolation and reverse transcriptase-polymerase
chain reaction. On day 7, the level of messenger RNA
(mRNA) for MMP-2 and VEGF was examined (n 5, per
group) by using reverse transcriptase-polymerase chain re-
action (RT-PCR). Isolation of total RNA was performed
using the Trizol reagent (Invitrogen, Carlsbad, Calif) ac-
cording to the manufacturer’s instructions. For this, 5 g
of total RNA was incubated with 100 U of SuperscriptTM
II reverse transcriptase (Invitrogen), deoxyribonucleotide
triphosphate (175M), oligo(dT) (200nM), dithiothreitol
(1M), and reaction buffer in a final volume of 20 L at
37°C for 60 min. After a final denaturation at 94°C for 5
minutes, 1 L of complimentary DNA was subjected to
polymerase chain reaction (PCR).
PCR amplifications used the following program: step 1,
94°C for 30 seconds; step 2, 53°C for 30 seconds; step 3,72°C for 30 seconds. Thirty cycles were performed for the
amplification of MMP-2 and VEGF.
PCR amplifications of -actin used the following pro-
gram: step 1, 94°C for 30 seconds; step 2, 56°C for 30
seconds; step 3, 72°C for 30 seconds; 30 cycles for -actin.
The last cycle was ended by 10 minutes of elongation at
72°C.
Sequences for mouseMMP-2, VEGF, and -actin were
obtained fromGenBank (Los Alamos, NM). The following
sequences of primers were used:
1. MMP-2: 5=GCT GCC ACG AGG AAT AGG 3=,
5=TCA ACG GTC GGG AAT ACA 3=;
2. VEGF: 5=AAG ATG AGG AAG GGT AAG C 3=,
5=GAG ACA ATG GGA TGA AAG G 3=;
3. -actin: 5=AAC CCT AAG GCC AAC CGT GAA AAG
3=, 5=TCA TGA GGT AGT CTG TCA GGT 3=.
The lengths of the MMP-2, VEGF, and -actin ampli-
cons were 490 bp, 556 bp and 242 bp, respectively. PCR
products were visualized on 1.5% agarose gels stained by
ethidium bromide and UV transillumination. Semiquanti-
tative analysis was conducted using a computerized densi-
tometric imager.
Preparation of tissue extracts. On day 7 after reper-
fusion, four mice per group were euthanized with an over-
dose of pentobarbital and then transcardially perfused with
ice-cold PBS (pH 7.4). The brains were removed quickly
and divided into ipsilateral and contralateral hemispheres.
Ischemic tissue and matching tissue from the contralateral
hemisphere was dissected, frozen immediately in liquid
nitrogen, and stored at 80°C. Brain samples were ho-
mogenized in lysis buffer (50mM Tris-HCl, pH 7.6;
150mM NaCl; 0.1% polyoxyethylene 23 lauryl ether, 0.1%
deoxycholic acid, 10 g/mL leupetin, 2 g/mL aprotinin,
1mM phenylmethylsulfonyl fluoride) on ice. After centrif-
ugation, the supernatant was collected, and total protein
concentrations were determined using the Bradford assay
(Bio-Rad, Hercules, Calif).
Western blot analysis. To investigate protein expres-
sion patterns in ischemic brains, equal amounts (40 g) of
total protein extracts were prepared. After mixing with 2
sample buffer, each sample was separated by Tris-glycine
sodium dodecyl sulfate polyacrylamide gel electrophoresis
(SDS-PAGE) in a reducing condition for MMP-2, VEGF
(anti-mouse MMP-2 and VEGF, Santa Cruz Biotechnol-
ogy), and -actin (antimouse -actin, Sigma). Proteins
were transferred after separation onto a polyvinylidene
diflouride membrane using a commercial semi-dry blotting
apparatus (Bio-Rad). All blots were blocked with 5% nonfat
dry milk in Tris-buffered saline (TBS; pH 7.4) containing
0.1% Tween 20 (TBS-T) at 4°C overnight.
Next, the filters were incubated with the primary
antibodies and diluted in blocking buffer for 2 hours at
room temperature. The respective dilution rates of the
primary antibodies were 1:400, 1:400, and 1:5000 for
MMP-2, VEGF, and -actin. The membrane was washed
with PBS-T and incubated with horseradish peroxidase-
conjugated secondary antibody at room temperature for
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dard chemical luminescence method (Santa Cruz Bio-
technology, Inc).
Statistical analysis. All values are given as mean 
standard deviation. Differences between groups were com-
pared by using analysis of variance with the Bonferroni
correction for multiple comparisons. Values of P 	 .05
were considered to indicate statistical significance.
RESULTS
Neurologic examination. The scores of OG and TG
mice were not different from those of CG mice on day 7
after MCA reperfusion (P  .05). However, the scores of
the IG and RG mice were lower than that of the CG mice
(P 	 .05; Fig 1).
TTC staining: infarct size. On day 7 after MCA
reperfusion, the infarct sizes of the OG and TG mice were
not different from those of the CG mice (P  .05). How-
ever, the infarct sizes of IG and RG mice were lower than
those of CG mice (P 	 .05; Fig 2).
Vascular density. The Table reports the reduction of
the number of the microvessels in the basal ganglia region
and the cortex for each study group compared with the
nonischemic side. In the cortical area of mice, the number
of the microvessels in IG and RG mice significantly ex-
ceeded the number of the microvessels in CG mice (P 	
.05).
MMP-2 and VEGF mRNA expression. To deter-
mine whether indeed resveratrol was involved in the regu-
lation of MMP-2 and VEGF at the mRNA level, we did a
Fig 1. Neurologic scores of mice 7 days after middle cerebral
artery reperfusion. 0, no apparent deficits; 1, left forelimb flexion;
2, decreased grip of the left forelimb while the tail is pulled; 3,
spontaneous movement in all directions; left circling only if pulled
by the tail; 4, spontaneous left circling. Scores for mice in the
ischemia group (IG) and reperfusion group (RG) are significantly
different from the control group (CG) scores (*P	 .05). Data are
given as means  standard deviation (n  8, per group). OG,
First-day group; TG, third-day group.semiquantitative RT-PCR. Although there was no statisti-cal difference among the five groups (P .05), we noted a
slight increase of MMP-2 and VEGF mRNAs level in IG
and RG mice, whereas -actin mRNA levels remained
unchanged (Fig 3).
MMP-2 and VEGF protein expression. To deter-
mine the effect of resveratrol on protein expression of
MMP-2 and VEGF, tissue extracts were analyzed by West-
ern blot. In Western blot analysis, tissue extracts from IG
and RG mice showed more strong immunoreactive bands
onWestern blots of MMP-2 and VEGF (P	 .05). Extracts
from OG mice did not show the significant up-regulation
of MMP-2 and VEGF. However, there was a slight de-
crease of VEGF protein expression in TG mice, but -actin
protein expression remained unchanged (Fig 4).
DISCUSSION
This current study showed two major findings. First,
resveratrol administration after stroke is beneficial to reduce
infarct volume and recover neurologic function in the
delayed phase after stroke. This notion is partly supported
Fig 2. Infarct volumes of mice in 7 days after middle cerebral
artery reperfusion. Volumes for mice in the ischemia group (IG)
and reperfusion group (RG) are significantly different (*P 	 .05)
from the control group (CG). Data are given as means standard
deviation (n  8, per group). OG, First-day group; TG, third-day
group.
Table. Reduction of CD34-stained microvessels in the
cortex and the basal ganglia on the ischemic side
compared with the nonischemic sidea
Groups (n  5) Cortex, % Basal ganglia, %
Control group 53  8 61  7
Ischemia group 93  5b 63  7
Reperfusion group 82  7b 65  8
First-day group 64  7 60  6
Third-day group 54  6 63  7
aData are given as means  standard deviation.
bThe ischemia group and reperfusion group are significantly different (P 	
.05) from the control group in the cortex on the ischemic side compared
with the nonischemic side.by the recent research that treatment with resveratrol (0.1
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decreased the lactate dehydrogenase in plasma and malon-
dialdehyde in focal cerebral ischemic injury brain tissue,
whereas the level of NO in plasma was increased.20
Second, the effect of resveratrol is more prominent in
the ischemia group and reperfusion group compared
with other groups on day 7 after MCA occlusion. This
means that the early resveratrol administration during the
ischemia–reperfusion injury might be more beneficial to
reduce infarct volume and recover neurologic function. In
addition, previous studies on the role of resveratrol on
ischemia–reperfusion injury concentrated on resveratrol
preconditioning.10-17 This study confirmed that early
treatment with resveratrol after ischemia was also bene-
ficial for brain protection and recovery of neurologic
function.
However, the mechanism of the protection of resvera-
trol after stroke remains to be studied. It was confirmed
that resveratrol could enhance myocardial angiogenesis
both in vivo and in vitro by inducing VEGF, and pretreat-
ment with resveratrol markedly reduced infarct size 24
hours after myocardial infarction and increased capillary
density in the peri-infarct myocardium.21 Fukuda et al22
demonstrated that resveratrol significantly up-regulated
the protein expression profiles of VEGF and increased
capillary density and also that pharmacologic precondition-
ing with resveratrol 3 weeks after myocardial infarction
improved left ventricular function.
In addition, resveratrol can markedly raise the prolifer-
ation, migration, and adhesion of endothelial progenitor
cells in vitro as well as endothelial progenitor cells mobili-
zation in a low dosage.23 These effects appear to be related
with angiogenesis. Our study also identified that angiogen-
esis induced by resveratrol might play an important role in
the delayed phase after stroke, and resveratrol significantly
up-regulated the expression of VEGF and MMP-2, which
Fig 3. Results of reverse transcriptase-polymerase chain reaction
assay for matrix metalloproteinase-2 (MMP-2) and vascular endo-
thelial growth factor (VEGF) in the delayed phases show a slight
increase occurred in MMP-2 and VEGF messenger RNAs level in
the ischemia group (IG) and reperfusion group (RG). Mouse
-actin was used as the internal standard. The sizes of MMP-2,
VEGF, and -actin were 490 bp, 556 bp, and 242 bp, respectively.
DNA markers (M) are as indicated on the left (n  5, per group).
CG, Control group; OG, first-day group; TG, third-day group.could induce angiogenesis.Angiogenesis is a very important factor in stroke recov-
ery. MMP-2 and VEGF may be crucial for this process
because they can remodel all components of extracellular
matrix and blood vessel formation. Our study is consistent
with these general principles. Given all these consider-
ations, we suggest that angiogenesis induced by resveratrol
might play important role in the delayed phase after stroke.
Together with the free radical scavenging, antiplatelet ag-
gregation, and anti-inflammatory effects of resveratrol in
Fig 4. Top, Western blot analysis of stroke-induced levels of
matrix metalloproteinase-2 (MMP-2) and vascular endothelial
growth factor (VEGF) in ischemic mouse brain tissue extracts in
the delayed phases. Data are representative examples. Results
showed that (Middle) MMP-2 and (Bottom) VEGF proteins in
the ischemia group (IG) and reperfusion group (RG) were ex-
pressed at a high level. Extracts from the first-day group (OG) and
third-day group (TG) did not showMMP-2 and VEGF significant
up-regulation. Mouse -actin was used as the internal standard.
Data are given as means  standard deviation (n  4, per group;
*P 	 0.05).preconditioning in cerebral ischemia–reperfusion injury,
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anti-ischemic drugs.
CONCLUSION
Our finding confirmed that resveratrol administration
after stroke is beneficial to reduce infarct volume and in the
recovery of neurologic function in the delayed phase after
stroke. Studies are underway to more completely define the
role of resveratrol in stroke and to determine how resvera-
trol may affect this process after stroke.
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